Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis and Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and Large Patient Populations

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3a6C8o3
via IFTTT